These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 5162009)

  • 21. [Application of valium in psychiatry].
    Aleksandrowicz J; Dzikowski H
    Neurol Neurochir Psychiatr Pol; 1965; 15(4):647-55. PubMed ID: 5843585
    [No Abstract]   [Full Text] [Related]  

  • 22. [Chlomipramine a major thymoanaleptic which acts on psychotic and chiefly schizophrenic anguish].
    Levy L; Langlois H; Caron J; Rouquette J; Hug R; Teboul S
    Encephale; 1967; 56(6):541-51. PubMed ID: 4881588
    [No Abstract]   [Full Text] [Related]  

  • 23. [Thoughts on indications of sulpiride in ambulatory therapeutics].
    Ernst J; Choteau P
    Lille Med; 1972 Jan; 17():Suppl 1:37-9. PubMed ID: 5026566
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of perphenazine in psychiatric emergencies: the concept of chemical restraint.
    Fann WE; Linton PH
    Curr Ther Res Clin Exp; 1972 Aug; 14(8):478-82. PubMed ID: 4629310
    [No Abstract]   [Full Text] [Related]  

  • 25. Neuroleptic malignant syndrome during perphenazine treatment.
    Nielsen D; Aunsholt NA; Andersen PT
    Pharmacol Toxicol; 1987 Mar; 60(3):221-2. PubMed ID: 3588517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the therapeutic effect of flupenthixol and perphenazine in schizophrenia.
    Náhunek K; Svestka J; Rodová A
    Act Nerv Super (Praha); 1970; 12(3):247-8. PubMed ID: 5457440
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of acetophenazine in office practice.
    Cook RW
    Int J Neuropsychiatry; 1965 Dec; 1(6):605-7. PubMed ID: 5894976
    [No Abstract]   [Full Text] [Related]  

  • 28. [Experiences with the benzodiazepin derivative valium].
    Podiwinsky F
    Wien Med Wochenschr; 1965 Aug; 115(32):649-52. PubMed ID: 5892064
    [No Abstract]   [Full Text] [Related]  

  • 29. [On the position of the butyrophenone derivative Haloperidol in psychiatric treatment].
    Greger J; Glitschka A; Müller K
    Psychiatr Neurol Med Psychol (Leipz); 1968 Jun; 20(7):241-52. PubMed ID: 5731879
    [No Abstract]   [Full Text] [Related]  

  • 30. [Experience with Luvatren in ambulatory psychiatric patients].
    Reiter PJ
    Schweiz Arch Neurol Neurochir Psychiatr; 1969; 104(1):169-78. PubMed ID: 5801171
    [No Abstract]   [Full Text] [Related]  

  • 31. [Trial of benzoctamine in psychiatry].
    Bézault G; Chatel B; Dehu J; Jouy JC
    Ann Med Psychol (Paris); 1972 Dec; 2(5):708-18. PubMed ID: 4576211
    [No Abstract]   [Full Text] [Related]  

  • 32. Placebo as prognosticator.
    Glick BS
    Dis Nerv Syst; 1967 Nov; 28(11):737-43. PubMed ID: 4863820
    [No Abstract]   [Full Text] [Related]  

  • 33. The chronic emotionally disturbed patient: an efficient management model.
    Stevenson JM
    W V Med J; 1973 Apr; 69(4):83-4. PubMed ID: 4512208
    [No Abstract]   [Full Text] [Related]  

  • 34. Dose-response relationships of perphenazine in the treatment of acute psychoses.
    Hansen LB; Larsen NE; Gulmann N
    Psychopharmacology (Berl); 1982; 78(2):112-5. PubMed ID: 6817364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxazepam in psychoneuroses and "anxiety bound" psychoses.
    Zador I
    Dis Nerv Syst; 1969 Oct; 30(10):688-92. PubMed ID: 5355301
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacological treatment of delusional depression].
    Amore M; Giordani L; Giorgetti G; Zazzeri N
    Minerva Psichiatr; 1996 Mar; 37(1):29-33. PubMed ID: 8804200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Observations on Melleril-induced EEG changes in mental patients and their relationship to course and outcome of the illness.
    Robinson S; Dasberg H
    Isr Ann Psychiatr Relat Discip; 1969 Nov; 7(2):201-12. PubMed ID: 5274358
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical efficacy of haloperidol in chronic psychotic patients.
    Lapolla A
    Int J Neuropsychiatry; 1967 Aug; 3():Suppl l:68-77. PubMed ID: 6051725
    [No Abstract]   [Full Text] [Related]  

  • 39. [Extension of therapeutic possibilities by a new tranquilizer].
    Leube H
    Arzneimittelforschung; 1968 Dec; 18(12):1566-8. PubMed ID: 5756250
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinico-statistical study of the effects of sulpiride, a new psychopharmacologic agent].
    Bente D; Koeller DM; Koufen H; Pietzcker A; Schulte PW
    Arzneimittelforschung; 1974 Jan; 24(1):107-11. PubMed ID: 4594226
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.